Pharma and Biotech Daily: M&A Surge and Regulatory Updates in the Industry

Pharma and BioTech Daily

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. A judge has suspended mass layoffs at the Department of Health and Human Services, ruling that the staff cuts are likely unlawful as the agency does not have the authority to make such changes without Congress. In other news, private equity firms have recently acquired Bluebird Bio, a gene therapy biotech company, raising questions about their motivations. Additionally, RFK Jr. is advocating for changes to the vaccine injury compensation program to include COVID-19 vaccines, while the FDA is considering regulatory action on Argenx's Vyvgart Hytrulo due to safety concerns. The article also discusses Gilead's plans for dominance in the HIV market with a new drug, and other updates in the pharmaceutical industry.Private equity firms are increasingly targeting biotech companies, with Bluebird Bio recently being acquired by two firms. The first half of the year saw a surge in M&A activity in the pharmaceutical industry, with big pharmas like Eli Lilly and Novartis making multiple deals. Deals related to Alzheimer's disease also saw a significant increase following the approval of new treatments. Gilead is expanding its presence in the HIV market with a new drug, while GSK is also vying for market dominance. Other notable deals include AbbVie's acquisition of Capstan and Novartis' partnership for cardiovascular disease targets. Overall, the industry is seeing increased activity and interest from private equity firms and big pharma companies.